LB Pharmaceuticals
Anna Eramo, MD, Psychiatrist, has been the Chief Medical Officer since Sep 2020. Dr. Eramo joins LB from Lundbeck, where she led United States Clinical and Medical Affairs with primary responsibilities extending across Lundbeck’s entire United States neurology and psychiatric portfolio of products, including brexpriprazole, vortioxetine, and Abilify Maintena. Dr. Eramo holds both an academic degree in medicine and a specialty degree in psychiatry and psychotherapy from the University Medical School of Naples, Italy.
This person is not in any teams
This person is not in any offices
LB Pharmaceuticals
1 followers
LB Pharmaceuticals is a drug development company focused on development treatments for CNS disorders. The company's lead compound is LB-102; a novel benzamide being developed the treatment of schizophrenia owned and development internally by LB. LB-102 recently completed a Phase 1 study; a First-in-patient study is planned for July 2021.